Maze Therapeutics, Inc. $MAZE Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 410.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,281 shares of the company’s stock after buying an additional 45,256 shares during the quarter. Profund Advisors LLC’s holdings in Maze Therapeutics were worth $1,530,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. raised its holdings in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after acquiring an additional 465,641 shares in the last quarter. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth approximately $133,502,907. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $122,983,582. BlackRock Inc. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $104,525,000. Finally, Jupiter Topco LLC bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $101,764,000.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $30.37 on Tuesday. The firm has a market capitalization of $1.69 billion, a PE ratio of -12.05 and a beta of 2.16. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12-month low of $21.95 and a 12-month high of $53.65. The firm has a 50-day moving average price of $27.51 and a 200 day moving average price of $31.94.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). Research analysts anticipate that Maze Therapeutics, Inc. will post -2.70 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider directly owned 7,007 shares in the company, valued at $182,252.07. This represents a 22.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 16,141 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer owned 16,141 shares of the company’s stock, valued at $434,677.13. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock worth $5,187,559 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on MAZE shares. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Canaccord Genuity Group assumed coverage on shares of Maze Therapeutics in a research note on Monday, October 19th. They set a “buy” rating and a $75.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $110.00 price target on shares of Maze Therapeutics in a report on Thursday, September 24th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average price target of $64.45.

Maze Therapeutics Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.